

**Working together to diagnose
and treat one of the world's
greatest unmet medical needs**

The Dementia Challenge

One of the world's greatest unmet medical needs

Epidemic

As the world's population ages, the prevalence of AD is predicted to reach epidemic proportions.

139 million

55m people currently living with AD predicted to rise to 78m by 2030 and 139m by 2050.

500 million

Estimated 500m people globally with clinically measurable early stages of progressive tau pathology.

Impact

Huge financial impact on public healthcare and devastating for patients, families and caregivers.

\$1.3 Trillion

Worldwide cost of dementia is forecast to increase from \$1.3tr in 2019 to \$2.8tr in 2050.

48%

48% of the 45+ population have brain tau pathology, indicating scope of prophylactic market.

Working together to diagnose and treat one of the world's greatest unmet medical needs

Whilst new treatments for dementia are required to address this global unmet medical need, it is widely recognised that more efficient and accurate diagnostic tools are necessary to ensure patient access to new medicines.

Collectively, TauRx and GT Diagnostics have a vision to transform the treatment landscape of Alzheimer's disease and other related neurodegenerative conditions bringing benefits to millions of patients and their families worldwide.



GT Diagnostics' mission is to develop readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia.



TauRx's mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused by protein aggregation.



GT DIAGNOSTICS

Accelerating Dementia Diagnosis

Genting TauRx Diagnostic Centre Sdn Bhd and its wholly owned subsidiary GT Diagnostics (UK) Limited (jointly GT Diagnostics) were formed to enable basic research in dementia diagnosis to transition into clinical development.

Our mission is to develop and provide much needed tools required for the early diagnosis and monitoring of disease progression in dementia; from tools that can be used in the comfort of one's home to tools that require administration by experts.


Globally, AD International estimates 75% of people with dementia are not diagnosed, that equates to 41 million people undiagnosed

Of the people aged 45+:


3 People in 500 are currently diagnosed with dementia.

9 people in 500 have dementia but are undiagnosed.

90 people in 500 have changes in their brain that could lead to dementia.



Current Patient Journey



The journey from initial suspicion to a diagnosis often feels like a long and winding road to patients; long wait periods between different appointments lengthen the time spent worrying. Clinicians see a major challenge in the increasing number of people who will be seeking a diagnosis in the future as a result of an aging global population.

New Patient Journey

- 1 Initial suspicion & self-assessment
- 2 Initial appointment with advanced diagnostic tools
- 3 Treatment & ongoing monitoring

GT Diagnostics envisions a more streamlined process in which the first steps are taken in the comfort of a person's home.

Reducing wait times by ensuring only the right people are referred further and leveraging technology to maximise the time clinicians have with patients will transform the patient journey.

Our Products

Our products are at various stages of development. For up-to-date information on availability in your region, please visit our website: www.gtdiag.com



An engaging and interactive well-being app that permits those concerned about their cognitive health to monitor their status at home.



A self-administered engaging and interactive tool running on a tablet, supporting clinicians in evaluating objective and subjective memory and mental processing speed.



A specialised neuropsychological testing tool for clinicians to use in their assessment of patients with suspected or confirmed dementia, including Alzheimer's disease.



A non-invasive, advanced EEG-based analysis tool, using standard EEG acquisition devices to provide an objective measure of brain connectivity.



In 2002, TauRx was founded in Singapore to facilitate the progression of basic research in neurodegenerative diseases to clinical development in Alzheimer's disease.

Since then, the company has remained dedicated to discovering a safe and effective treatment for Alzheimer's disease, the cause of over 50% of dementia cases.

TauRx's efforts to finding a treatment are complemented by a desire to reduce the stigma associated with the disease and promote early diagnosis. This is particularly important as new medicines are likely to have the greatest impact in the early stages of the disease.

From this initial foundation of bringing to market a potential future disease modifying treatment for Alzheimer's, the TauRx group of companies has grown over time. TauRx's progress in this area has been made possible by the dedication and significant investment of its loyal shareholder base.

The Key Proteins in Dementia

Many neurodegenerative diseases share common pathological features: the misfolding and aggregation of key proteins. Under normal circumstances, cellular mechanisms efficiently degrade these proteins into their components for recycling.

However, in some cases the misfolding leads to protein aggregation, which can then lead into an aggregation cascade that is self-propagating. Ultimately, misfolding of proteins and protein aggregation undermine a cell's operational efficiency and the process becomes toxic.

The 2 main proteins known to be involved in AD are amyloid and tau.

Amyloid


- For the past 20 years, Alzheimer's disease research and drug development have largely been dominated by amyloid.
- The Hypothesis was that the formation of **β-amyloid plaques** in the brain plays a central role in clinical dementia.
- But **β-amyloid plaques are poorly correlated with dementia**, and many results from clinical trials based on this approach have not produced the desired results.

Tau

- The **TauRx** research team has been focusing on the **tau hypothesis** for nearly three decades.
- Abnormal aggregation of tau protein ultimately leads to the formation of tangles within nerve cells in the brain.
- Tau aggregation process continues of its own accord, consuming the normal form of tau protein in the process and spreading the aggregation cascade into previously healthy nerve cells.
- **Tau pathology correlates well with disease progression and clinical symptoms of dementia.**

Tau pathology correlates with disease progression

- Braak staging is used in diagnosis, and is based on the spread of tau tangles in the brain.
- In Alzheimer's disease, clinical decline, scan deficits and brain atrophy **correlate with pathological tau load.**
- Braak stage 2 = pre-/mild AD.



Estimated population at Braak stage 2 = 646 million in 2025

TauRx was founded on the basis of two breakthrough discoveries:

1

Identification of the core tau unit of the Alzheimer tangle filament


(PHF; Wischik et al., 1988)



2


Discovery of hydromethylthionine class of molecules able to dissolve paired helical filaments and block tau aggregation

(Wischik et al., 1996)



- The detailed research and development program for TauRx's lead compound, hydromethylthionine mesylate (HMTM) was based on these key discoveries.
- HMTM is a tau aggregation inhibitor, which works by interfering with the damaging process of tau misfolding and aggregation, to promote the normal and healthy function of tau in brain cells.

Status of TauRx's Phase 3 LUCIDITY Trial



A randomized, double-blind, placebo-controlled, 12-month, safety and efficacy study of TRx0237 (HMTM) 16 mg/day monotherapy in subjects with Alzheimer's disease followed by 12-month open-label treatment.

- HMTM is the **only drug targeting tau for Mild Cognitive Impairment** due to Alzheimer's, mild, and mild-moderate Alzheimer's disease in late-stage trials.
- Phase 3 Lucidity trial outcomes are designed for clinical meaningfulness (psychometric scales) and biomarker certainty (MRI and blood-based biomarkers).
- With **compelling results** and a path to regulatory submissions, TauRx are working towards potential US launch in late 2024.
- HMTM has been designed to be an **affordable, accessible, oral therapy** with a benign safety profile following testing in over 2,000 patients to date.



More information on the Lucidity Trial



Dr Glenn Corr
COO/CBO

T: +44 1224 440902
M: +44 7891 508732
E: g.corr@taurx.com



Rebecca Andersen
COMMERCIAL DIRECTOR

T: +44 1224 440970
M: +44 7979 082304
E: r.andersen@taurx.com



www.taurx.com



Bjoern Schelter
CEO

T: +44 1224 440991
M: +44 7964 915687
E: b.schel@gtdiag.com



www.gtdiag.com



Linda Sommerlade
HEAD OF OPERATIONS

T: +44 1224 440992
M: +44 7934 818486
E: l.sommerlade@gtdiag.com



Scan to view profiles

